Trauma and Stressor-Related Disorders
Acute Stress Disorder drug pipeline
2 compounds from 2 companies are in active clinical development for acute stress disorder.
2Compounds
2Companies
0Phase 3+
2Upcoming readouts
2Trials recruiting
- Phase 2 2
Mechanisms: Small molecule (2)
Pipeline data compiled July 2026 · every fact sourced.
Upcoming readouts & recent results
Phase 2a RISE study of sublingual dexmedetomidine (BXCL501) in acute stress reactions after motor vehicle collision: topline expected after the estimated Sep 2026 primary completion. ↗
Phase 2 OASIS topline (TNX-102 SL for acute stress reaction/disorder in ED trauma survivors) anticipated in 2H 2026. ↗
Compounds in development (2)
| Compound | Company | Phase | Status | Mechanism |
|---|---|---|---|---|
| Dexmedetomidine sublingual film (BXCL501) | BioXcel Therapeutics, Inc. | Phase 2 | Recruiting | alpha-2A adrenoceptor Agonist |
| TNX-102 SL (cyclobenzaprine HCl sublingual) | Tonix Pharmaceuticals Holding Corp. | Phase 2 | Recruiting | H1 receptor Antagonist |
Trials recruiting now (2)
2 drug-interventional acute stress disorder trials recruiting now, of 2 registered interventional trials. Browse all on ClinicalTrials.gov →
BXCL501 (dexmedetomidine HCl), Placebo
Cyclobenzaprine HCl, Placebo
Frequently asked
- How many drugs are in development for acute stress disorder?
- 2 compounds from 2 companies are in active clinical development for acute stress disorder.
- What are the next acute stress disorder trial readouts?
- Upcoming catalysts include Dexmedetomidine sublingual film (BXCL501) (2H 2026) and TNX-102 SL (cyclobenzaprine HCl sublingual) (2H 2026).
- How many clinical trials are recruiting for acute stress disorder?
- 2 drug-interventional acute stress disorder trials are currently recruiting participants, out of 2 registered interventional trials.